Skip to content
zameds

Brinzolamide, timolol

Sold as Azarga

Loading the molecular structure
C13H24N4O3S316.42 g/mol

(2S)-1-(tert-Butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol

Drag to rotate. Structure from PubChem CID 33624.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
1
Registrations
1

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Novartis South Africa (Pty) LtdAzargaNot stated440046Not determinedNone

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Azarga

EACH 1,0 ml SUSPENSION CONTAINS BRINZOLAMIDE 10,0 mg TIMOLOL MALEATE EQUIVALENT TO TIMOLOL 5,0 mg

Not listed44004644/15.4/0046RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Bimatoprost

    Consolidated Schedules 06 July 2026, line 5499

  • S4: Latanoprost

    Consolidated Schedules 06 July 2026, line 6878

  • S4: Travoprost

    Consolidated Schedules 06 July 2026, line 8272

  • S3: Brinzolamide

    Consolidated Schedules 06 July 2026, line 3235

  • S3: Dorzolamide

    Consolidated Schedules 06 July 2026, line 3486

  • S3: Timolol

    Consolidated Schedules 06 July 2026, line 4325

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading...
Loading PubMed articles